 | Up a level |
2017
Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J., Collins, G., Ramchandren, R., Cohen, J., De Boer, J. P., Kuruvilla, J., Savage, K., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL. Haematologica, 102. S. 145 - 146. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Jaeger, U., Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., De Boer, J. P., Kuruvilla, J., Savage, K. J., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncol. Res. Treat., 40. S. 13 - 15. BASEL: KARGER. ISSN 2296-5262